Coherus Biosciences Inc (CHRS) Given Consensus Rating of “Buy” by Brokerages

Shares of Coherus Biosciences Inc (NASDAQ:CHRS) have received an average recommendation of “Buy” from the eleven analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $32.00.

Several analysts have recently commented on CHRS shares. BidaskClub upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Zacks Investment Research lowered shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. ValuEngine lowered shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, November 10th. Finally, Citigroup reiterated a “buy” rating and issued a $23.00 price target on shares of Coherus Biosciences in a research report on Tuesday, November 7th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Temasek Holdings Private Ltd acquired a new stake in Coherus Biosciences during the third quarter worth approximately $87,524,000. Vanguard Group Inc. boosted its position in Coherus Biosciences by 2.1% during the second quarter. Vanguard Group Inc. now owns 2,255,467 shares of the biotechnology company’s stock worth $32,367,000 after acquiring an additional 46,223 shares during the last quarter. Citadel Advisors LLC boosted its position in Coherus Biosciences by 819.9% during the fourth quarter. Citadel Advisors LLC now owns 1,772,241 shares of the biotechnology company’s stock worth $15,595,000 after acquiring an additional 1,579,582 shares during the last quarter. State Street Corp boosted its position in Coherus Biosciences by 26.8% during the second quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock worth $20,329,000 after acquiring an additional 298,986 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in Coherus Biosciences by 5.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,393,661 shares of the biotechnology company’s stock worth $12,264,000 after acquiring an additional 72,710 shares during the last quarter. Hedge funds and other institutional investors own 78.80% of the company’s stock.

Shares of Coherus Biosciences (NASDAQ:CHRS) traded down $0.10 during trading on Wednesday, reaching $9.65. 228,100 shares of the company’s stock were exchanged, compared to its average volume of 703,119. The stock has a market capitalization of $583.45, a PE ratio of -1.78 and a beta of 3.81. Coherus Biosciences has a 12 month low of $8.05 and a 12 month high of $26.55. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/coherus-biosciences-inc-chrs-given-consensus-rating-of-buy-by-brokerages.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply